Skip to main content
73°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Denali Therapeutics Inc.
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following
August 14, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
August 01, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
June 03, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 07, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
May 01, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
February 27, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces $500 million Private Placement Equity Financing
February 27, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
February 07, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
February 01, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 08, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
November 07, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
August 30, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 08, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)
June 20, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
May 08, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
April 12, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
BIIB
DNLI
Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
April 10, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
February 27, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™
February 22, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™
February 15, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
January 25, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 09, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial
December 05, 2022
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
November 03, 2022
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN
November 01, 2022
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 24, 2022
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock
October 19, 2022
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Proposed Offering of Common Stock
October 18, 2022
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
October 03, 2022
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
BIIB
DNLI
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.